Branched-chain amino acids (BCAAs) are three of the nine essential amino acids: leucine, isoleucine and valine. The body cannot make them, so they must come from food. They are present in every complete protein, and they are also sold on their own as powders and capsules marketed for muscle growth, recovery and endurance.

The most important fact is that BCAAs alone are an incomplete set of building blocks. Muscle needs all nine essential amino acids to build new protein. In the one tracer study of BCAAs taken by mouth after lifting, they raised muscle protein synthesis by 22% over placebo, about half the response seen with whey protein supplying a similar amount of BCAAs (Jackman et al., Front Physiol 2017). Pooled trials suggest less muscle soreness after hard exercise, but no clear gain in performance, strength or lean mass. Most of these trials did not report how much protein participants ate in total.

This page summarizes what clinical trials, meta-analyses and regulators report. It is for education only and is not medical advice.

Property	Detail
Class	Essential amino acids (leucine, isoleucine, valine); dietary supplement ingredient
Dietary sources	Present in all complete proteins; 20 g of whey protein typically supplies ≈4.8–5.6 g of BCAAs
Route	Oral (powders, capsules, drinks); intravenous BCAA solutions are used in some liver-disease trials
Common ratio in trials	2:1:1 leucine:isoleucine:valine in many studies
Doses studied in exercise trials	5.6–20 g per session; 9 g/day in an 8-week trial; weight-based doses over 200 mg/kg/day
Plasma kinetics	Leucine and isoleucine rose ≈300% and valine ≈144%, peaking 0.5 h after a 5.6 g drink; no formal half-life for supplements
Key mechanism	Leucine switches on mTORC1, the cell’s protein-synthesis signal; the other six essential amino acids still have to come from somewhere
US status	Sold as a dietary supplement; FDA does not approve supplements before sale
WADA status	Not named on the 2026 Prohibited List

What it is

Muscle protein is built from 20 amino acids. Nine are essential, meaning the body cannot make them in useful amounts. The three BCAAs are among those nine (Wolfe, JISSN 2017). They are named for the branched carbon side chain they share.

Leucine gets the most attention. Besides being a building block, it acts as a signal that turns on mTORC1 (mechanistic target of rapamycin complex 1), a switch that starts protein synthesis in muscle cells. In a crossover study of 8 trained volunteers, this signal (measured as S6K1 activity 90 minutes after lifting) rose in the order placebo, leucine, BCAAs, then a full essential amino acid (EAA) mix, with a ninefold rise in the EAA trial (Moberg et al., Am J Physiol Cell Physiol 2016). Leucine is also the parent compound of HMB, which is sold as a separate supplement.

Why BCAAs alone have a built-in limit

Wolfe’s 2017 review lays out the core problem. To build new muscle protein, all nine essential amino acids must be present. If only three are taken in, the other six can only come from breaking down existing muscle protein (Wolfe, JISSN 2017).

In the fasted state, muscle protein breakdown runs about 30% faster than synthesis. So, Wolfe argues, BCAAs alone can at most help recycle amino acids from breakdown more efficiently. He estimated this could raise synthesis by about 15% at best, and could never push muscle into a net-building state. His search found no human study that had measured muscle protein synthesis after oral BCAAs alone. The only two human studies (both using intravenous BCAAs) found that synthesis and breakdown both fell, and muscle stayed in net breakdown.

The review’s author declared research grants or honoraria from food companies, along with other commercial ties listed in the paper.

How it works in the body

After a 5.6 g BCAA drink in 10 trained men, plasma leucine and isoleucine rose about 300% and valine about 144%, all peaking 30 minutes after the drink (Jackman et al., Front Physiol 2017). In the same study, blood levels of phenylalanine (another essential amino acid) were lower 3 hours after the BCAA drink, which the authors linked to limited availability of the other essential amino acids.

BCAAs also compete with tryptophan for the same carrier into the brain. Tryptophan is the raw material for serotonin, which has been proposed as a driver of “central” (brain-level) fatigue during long exercise. Raising blood BCAAs could, in theory, reduce tryptophan entry into the brain (Blomstrand, J Nutr 2006). This is the basis of the endurance claims covered below.

High intakes have a ceiling. In a stepwise study in 5 healthy men, the body’s ability to oxidize leucine topped out at 550–700 mg/kg/day. Blood ammonia rose above 500 mg/kg/day, and the authors suggested intakes above 550 mg/kg/day, about 39 g of leucine a day, may carry risk (Pencharz et al., J Nutr 2012). These were short-term tests only.

Regulatory status

In the US, BCAA products are sold as dietary supplements. By law, FDA does not approve dietary supplements or their labeling before sale, and it does not routinely test their contents (FDA). Separately, L-leucine, L-isoleucine and L-valine are listed food additives that may be added to foods to improve protein quality, within set limits (21 CFR 172.320).

BCAAs are not named on the WADA 2026 Prohibited List.

What the research shows

Muscle protein synthesis: BCAAs vs complete protein

Three tracer studies frame the debate:

Study	Design	What was given	Result
Jackman et al., 2017	Crossover, 10 trained young men, after leg exercise	5.6 g BCAAs vs placebo	Myofibrillar protein synthesis 22% higher with BCAAs (0.110 vs 0.090 %/h)
Churchward-Venne et al., 2012	24 men, after one-leg exercise	25 g whey vs 6.25 g whey plus leucine vs 6.25 g whey plus other EAAs	No difference at 1–3 h; at 3–5 h after exercise only 25 g whey stayed significantly above fasting (rise of 184% vs 55% and 35%)
Moberg et al., 2016	Crossover, 8 trained volunteers	Placebo vs leucine vs BCAAs vs full EAA mix	Signaling rose in that order; EAAs strongest (signaling only, not synthesis rates)

The Jackman study is the main evidence that BCAAs alone can raise muscle protein synthesis. The authors themselves noted that the 22% rise was about 50% smaller than the response previously seen with whey protein containing a similar amount of BCAAs. They concluded that a full set of essential amino acids is likely needed for a maximal response. The 5.6 g dose was chosen because it matches the BCAA content of a typical 20 g whey serving.

The International Society of Sports Nutrition advises protein doses that contain 700–3000 mg of leucine together with a balanced array of the other essential amino acids. It states that the essential amino acids are what is required to stimulate muscle protein synthesis (Jäger et al., JISSN 2017). The same position stand puts daily protein needs for most exercising people at 1.4–2.0 g/kg/day.

Muscle mass and strength over time

Long-term trials do not show added gains. In an 8-week trial, 19 untrained men lifted weights 4 times a week and took 9 g/day of BCAAs or placebo on training days. Strength and muscular endurance rose with training in both groups, with no difference between them and no change in fat-free mass (Spillane et al., Nutr Health 2012).

A 2022 systematic review of 24 studies in athletes and regular exercisers found that, although BCAAs tended to activate anabolic signals, benefits on performance and body composition were “negligible.” It also noted that most studies did not report participants’ total daily protein intake (Martinho et al., Nutrients 2022). This matters because anyone already eating enough complete protein is already taking in BCAAs with all the other essential amino acids.

Muscle soreness and damage

This is the outcome with the most support. “DOMS” means delayed-onset muscle soreness, the ache that peaks a day or two after unaccustomed exercise. Creatine kinase (CK) is an enzyme that leaks from damaged muscle into the blood.

Meta-analysis	Studies	Main findings
Rahimi et al., 2017	8 trials	Lower CK at under 24 h (−71.6 U/L) and 24 h (−145.0 U/L); no significant effect on soreness or LDH at any time
Fedewa et al., 2019	8 studies, 61 participants on BCAAs	Less DOMS, effect size 0.73 (95% CI 0.50–0.96)
Doma et al., 2021	25 studies, 479 participants	Lower damage markers at 48 h (SMD −0.41) and less soreness at 24 and 48 h; no difference in muscle performance at 24 or 48 h
Khemtong et al., 2021	9 trials, trained men after resistance exercise	Lower CK up to 48 h; less soreness only before 24 h; no effect on LDH
Weber et al., 2021	9 trials in meta-analysis	7 of 10 studies showed less DOMS at 24–72 h; high variability between studies
Salem et al., 2024	18 studies	Less DOMS at 24, 48, 72 and 96 h (Hedges’ g −1.34 to −1.82 at 24–72 h); CK lower only immediately and at 72 h; no effect on LDH

The direction of these results is fairly consistent for soreness and CK, but the trials are small and differ widely in dose, timing, training status and type of exercise. Note that the Rahimi abstract concludes BCAAs reduce soreness even though its own pooled soreness results were not significant (a corrigendum was published in 2018). An umbrella review graded the evidence for BCAAs reducing DOMS as moderate certainty (Talebi et al., Nutr Rev 2024).

Less soreness has not translated into faster recovery of strength or power in the largest pooled analysis (Doma et al., 2021). One meta-regression linked higher daily and total doses and longer supplementation to larger effects (Salem et al., 2024). A 2017 systematic review of 11 studies concluded the benefit appeared mainly when damage was low to moderate, the daily intake was over 200 mg/kg/day, and supplementation lasted more than 10 days (Fouré and Bendahan, Nutrients 2017).

None of these meta-analyses tested BCAAs against an equal amount of complete protein, so they cannot show whether BCAAs do anything that ordinary protein would not.

Endurance and central fatigue

The central fatigue theory has mixed support in performance trials:

Study	Design	Result
Blomstrand et al., 1991	BCAAs during a 30 km cross-country race or a marathon	Better post-race scores on a mental test (Stroop); marathon times improved only in slower runners (3.05–3.30 h), not faster runners
van Hall et al., 1995	Crossover, 10 endurance-trained men cycling to exhaustion; 6% sucrose drinks with 6 g/L or 18 g/L BCAAs, or tryptophan	No difference in time to exhaustion (≈122 min in all trials)
Madsen et al., 1996	Crossover, 9 trained cyclists, 100 km time trial; glucose, glucose plus BCAAs, or placebo	No difference in finishing time (≈157–160 min); blood ammonia higher with BCAAs

In the Blomstrand field study, the marathon benefit appeared only in a subgroup defined by finishing time. The two controlled laboratory crossover trials found no performance effect. Blomstrand has noted that carbohydrate intake during exercise may itself blunt any BCAA effect on brain tryptophan uptake (Blomstrand, J Nutr 2006). The 2022 systematic review found the endurance findings inconsistent (Martinho et al., Nutrients 2022).

Medical use: hepatic encephalopathy

BCAAs have a medical role in liver disease. Hepatic encephalopathy is brain dysfunction caused by liver failure. A 2026 Cochrane review of 18 randomized trials (934 adults, nearly all with cirrhosis) found BCAAs, oral or intravenous, reduced hepatic encephalopathy (RR 0.79, 95% CI 0.64–0.96; low-certainty evidence), with no clear effect on mortality (RR 0.89, 95% CI 0.71–1.12) (Aamann et al., Cochrane 2026). This is a medical setting under clinical supervision and says nothing about use in healthy athletes.

Typical studied doses

These are doses used in the trials cited above, not recommendations:

Context	Dose and schedule	Source
Acute muscle protein synthesis	5.6 g once, right after exercise	Jackman et al., 2017
8-week resistance training	9 g/day on training days, split before and after exercise	Spillane et al., 2012
Muscle damage (pooled)	Benefit mainly with over 200 mg/kg/day for over 10 days	Fouré and Bendahan, 2017
DOMS (pooled)	Benefit seen at doses up to 255 mg/kg/day in trained people	Weber et al., 2021
Endurance cycling	6 or 18 g/L in a sucrose drink during exercise	van Hall et al., 1995

Side effects and risks

General tolerability

In healthy adults in exercise trials, BCAAs have generally been well tolerated, but few trials report adverse events systematically. In the Cochrane review of liver patients, nausea and diarrhea were reported in 12% of people on BCAAs vs 3% on control diets, though the pooled estimate was very uncertain (RR 2.05, 95% CI 0.40–10.58) (Aamann et al., Cochrane 2026).

Very high leucine intake

In the short-term stepwise study, leucine intakes above 500 mg/kg/day raised blood ammonia, and blood glucose fell (while staying in the normal range). Liver enzymes did not change (Pencharz et al., J Nutr 2012). Higher blood ammonia was also seen when BCAAs were added to glucose drinks during a 100 km cycling trial (Madsen et al., 1996).

ALS trials

High-dose BCAAs were once tested as a treatment for amyotrophic lateral sclerosis (ALS). An Italian placebo-controlled trial (leucine 12 g, isoleucine 6 g and valine 6 g daily) was stopped early by its data monitoring committee after 126 patients, because of excess deaths in the BCAA group (24 vs 13) and no benefit on disability (Italian ALS Study Group, Neurology 1993). A US trial of 95 patients found no benefit over 6 months, and lung function (forced vital capacity) declined about 2.5 times faster on BCAAs or threonine than on placebo; the authors could not rule out harm (Tandan et al., Neurology 1996).

Maple syrup urine disease

Maple syrup urine disease (MSUD) is an inherited disorder in which the body cannot break down BCAAs. Treatment is a diet that restricts leucine, with BCAA-free medical foods and careful supplementation of isoleucine and valine under specialist monitoring. Build-up of BCAAs can cause severe brain toxicity (Strauss et al., GeneReviews). For people with MSUD, BCAA intake is managed as part of specialist treatment.

Product quality

Because FDA does not approve supplements before sale or routinely test them, label accuracy depends on the manufacturer (FDA).

Key takeaways

An incomplete protein. BCAAs are three of the nine essential amino acids. Muscle needs all nine to build new protein, so BCAAs alone cannot sustain a full building response.
Smaller effect than whole protein. In the key tracer study, 5.6 g of BCAAs raised muscle protein synthesis by 22% after lifting, about half the response to whey with similar BCAA content.
Little added value with adequate protein. An 8-week training trial and a 24-study review found no meaningful gain in muscle, strength or performance, and most trials did not account for total protein intake.
Some support for less soreness. Several meta-analyses found less DOMS and lower CK after hard exercise, mostly in small trials, without faster recovery of strength.
Endurance claims are weak. Controlled cycling trials found no performance benefit, despite the central fatigue theory.
Generally tolerated, with exceptions. Very high leucine intakes raise ammonia, ALS trials raised safety concerns, and people with MSUD must avoid them. For related supplements, see creatine, glutamine and HMB.

Sources

Wolfe RR. Branched-chain amino acids and muscle protein synthesis in humans: myth or reality? J Int Soc Sports Nutr. 2017;14:30. PubMed.
Jackman SR, Witard OC, Philp A, et al. Branched-chain amino acid ingestion stimulates muscle myofibrillar protein synthesis following resistance exercise in humans. Front Physiol. 2017;8:390. PubMed.
Churchward-Venne TA, Burd NA, Mitchell CJ, et al. Supplementation of a suboptimal protein dose with leucine or essential amino acids: effects on myofibrillar protein synthesis at rest and following resistance exercise in men. J Physiol. 2012;590(11):2751–2765. PubMed.
Moberg M, Apró W, Ekblom B, et al. Activation of mTORC1 by leucine is potentiated by branched-chain amino acids and even more so by essential amino acids following resistance exercise. Am J Physiol Cell Physiol. 2016;310(11):C874–C884. PubMed.
Jäger R, Kerksick CM, Campbell BI, et al. International Society of Sports Nutrition position stand: protein and exercise. J Int Soc Sports Nutr. 2017;14:20. PubMed.
Spillane M, Emerson C, Willoughby DS. The effects of 8 weeks of heavy resistance training and branched-chain amino acid supplementation on body composition and muscle performance. Nutr Health. 2012;21(4):263–273. PubMed.
Martinho DV, Nobari H, Faria A, et al. Oral branched-chain amino acids supplementation in athletes: a systematic review. Nutrients. 2022;14(19):4002. PubMed.
Rahimi MH, Shab-Bidar S, Mollahosseini M, et al. Branched-chain amino acid supplementation and exercise-induced muscle damage in exercise recovery: a meta-analysis of randomized clinical trials. Nutrition. 2017;42:30–36. PubMed.
Fedewa MV, Spencer SO, Williams TD, et al. Effect of branched-chain amino acid supplementation on muscle soreness following exercise: a meta-analysis. Int J Vitam Nutr Res. 2019;89(5-6):348–356. PubMed.
Doma K, Singh U, Boullosa D, et al. The effect of branched-chain amino acid on muscle damage markers and performance following strenuous exercise: a systematic review and meta-analysis. Appl Physiol Nutr Metab. 2021;46(11):1303–1313. PubMed.
Khemtong C, Kuo CH, Chen CY, et al. Does branched-chain amino acids (BCAAs) supplementation attenuate muscle damage markers and soreness after resistance exercise in trained males? A meta-analysis of randomized controlled trials. Nutrients. 2021;13(6):1880. PubMed.
Weber MG, Dias SS, de Angelis TR, et al. The use of BCAA to decrease delayed-onset muscle soreness after a single bout of exercise: a systematic review and meta-analysis. Amino Acids. 2021;53(11):1663–1678. PubMed.
Salem A, Ben Maaoui K, Jahrami H, et al. Attenuating muscle damage biomarkers and muscle soreness after an exercise-induced muscle damage with branched-chain amino acid (BCAA) supplementation: a systematic review and meta-analysis with meta-regression. Sports Med Open. 2024;10(1):42. PubMed.
Talebi S, Mohammadi H, Zeraattalab-Motlagh S, et al. Nutritional interventions for exercise-induced muscle damage: an umbrella review of systematic reviews and meta-analyses of randomized trials. Nutr Rev. 2024;82(5):639–653. PubMed.
Fouré A, Bendahan D. Is branched-chain amino acids supplementation an efficient nutritional strategy to alleviate skeletal muscle damage? A systematic review. Nutrients. 2017;9(10):1047. PubMed.
Blomstrand E. A role for branched-chain amino acids in reducing central fatigue. J Nutr. 2006;136(2):544S–547S. PubMed.
Blomstrand E, Hassmén P, Ekblom B, et al. Administration of branched-chain amino acids during sustained exercise: effects on performance and on plasma concentration of some amino acids. Eur J Appl Physiol Occup Physiol. 1991;63(2):83–88. PubMed.
van Hall G, Raaymakers JS, Saris WH, et al. Ingestion of branched-chain amino acids and tryptophan during sustained exercise in man: failure to affect performance. J Physiol. 1995;486(Pt 3):789–794. PubMed.
Madsen K, MacLean DA, Kiens B, et al. Effects of glucose, glucose plus branched-chain amino acids, or placebo on bike performance over 100 km. J Appl Physiol. 1996;81(6):2644–2650. PubMed.
Pencharz PB, Elango R, Ball RO. Determination of the tolerable upper intake level of leucine in adult men. J Nutr. 2012;142(12):2220S–2224S. PubMed.
Aamann L, Deshpande N, Dam G, et al. Branched-chain amino acids for people with cirrhosis and hepatic encephalopathy. Cochrane Database Syst Rev. 2026;1(1):CD001939. PubMed.
Italian ALS Study Group. Branched-chain amino acids and amyotrophic lateral sclerosis: a treatment failure? Neurology. 1993;43(12):2466–2470. PubMed.
Tandan R, Bromberg MB, Forshew D, et al. A controlled trial of amino acid therapy in amyotrophic lateral sclerosis: I. Clinical, functional, and maximum isometric torque data. Neurology. 1996;47(5):1220–1226. PubMed.
Strauss KA, Puffenberger EG, Carson VJ. Maple syrup urine disease. In: Adam MP, et al., eds. GeneReviews. University of Washington, Seattle; 2006 (updated 2020). PubMed.
Food and Drug Administration. Questions and answers on dietary supplements. FDA.
Code of Federal Regulations. 21 CFR 172.320, Amino acids. eCFR.
World Anti-Doping Agency. The 2026 Prohibited List. WADA.

BCAA